A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
Recruiting · NCT05668403 · Registry updated 2026-04-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy | Primary Membranous Nephropathy | Recruiting | Phase 1 | 2026-04-30 | NCT05668403 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Jiaolian Drug Research and Development Co., Ltd | 6 |
| Shanghai Pharmaceuticals Holding Co., Ltd | 20 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hebei General Hospital | Shijiazhuang | China | 3 |
| Longhua Hospital Shanghai University of Traditional Chinese Medicine | Shanghai | China | 1 |
| Peking university first hospital | Beijing | China | 1 |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | China | 1 |
| The First Affiliated Hospital,College of Medicine,Zhejiang University | Hangzhou | China | 1 |